Reckitt Benckiser Group PLC Investors: Please contact the Portnoy Law Firm to recover your losses; August 4, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Reckitt Benckiser Group PLC is facing a class action lawsuit from investors due to alleged misleading statements and failure to disclose health risks associated with its Enfamil infant formula, leading to significant stock price declines [3][4][5]. Group 1: Class Action Details - The class action represents investors who purchased Reckitt Benckiser securities between January 13, 2021, and July 28, 2024, with a deadline for filing a lead plaintiff motion set for August 4, 2025 [1]. - The lawsuit claims that Reckitt Benckiser did not adequately warn consumers and investors about the increased risk of Necrotizing Enterocolitis (NEC) for preterm infants consuming its cow's milk-based formula [3]. Group 2: Legal Outcomes and Financial Impact - A jury verdict on March 15, 2024, found Mead Johnson negligent, resulting in a $60 million award for failing to warn about NEC risks, which caused Reckitt Benckiser's American Depositary Shares (ADSs) to drop nearly 14% [4]. - Following a related case on July 29, 2024, where a Missouri jury awarded $495 million in damages over NEC caused by a competing formula, Reckitt Benckiser's ADSs fell nearly 9% [5].